181 related articles for article (PubMed ID: 23700188)
1. Available evidence and outcome of off-label use of rituximab in clinical practice.
Danés I; Agustí A; Vallano A; Martínez J; Alerany C; Ferrer A; López A; Cortés-Hernández J; Bosch JA
Eur J Clin Pharmacol; 2013 Sep; 69(9):1689-99. PubMed ID: 23700188
[TBL] [Abstract][Full Text] [Related]
2. Experience with low-dose rituximab in off-label indications at two tertiary hospitals.
Chay J; Donovan P; Cummins L; Kubler P; Pillans P
Intern Med J; 2013 Aug; 43(8):871-82. PubMed ID: 23919335
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of off-label drug uses in hospitals: a multicentric prospective study.
Danés I; Agustí A; Vallano A; Alerany C; Martínez J; Bosch JA; Ferrer A; Gratacós L; Pérez A; Olmo M; Marron SM; Valderrama A; Bonafont X
Eur J Clin Pharmacol; 2014 Nov; 70(11):1385-93. PubMed ID: 25196202
[TBL] [Abstract][Full Text] [Related]
4. Prospective data collection of off-label use of rituximab in Australian public hospitals.
O'Connor K; Liddle C
Intern Med J; 2013 Aug; 43(8):863-70. PubMed ID: 23735074
[TBL] [Abstract][Full Text] [Related]
5. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
6. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
7. [Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital].
Conde García MC; Fernández Feijoo MA; Calleja Hernández MA
Farm Hosp; 2009; 33(6):305-11. PubMed ID: 20038389
[TBL] [Abstract][Full Text] [Related]
8. Rituximab as a rescue therapy in patients with glomerulonephritis.
Souqiyyeh MZ; Shaheen FA; Alsuwaida A; Alghonaim M; Alwakeel J; Mosa D; Akhtar F; Rahman E; Husain M; Roujouleh H; Siddiqi N; Bukhari I; Sadaqa N; Mushtaque F; Awn NM; Shariya F; Alfi A; Amin M; Ahmad M; Rowaie FA; Almueilo S; Kechrid MC; Karkar A
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):47-55. PubMed ID: 25579715
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
Witt M; Grunke M; Proft F; Baeuerle M; Aringer M; Burmester G; Chehab G; Fiehn C; Fischer-Betz R; Fleck M; Freivogel K; Haubitz M; Kötter I; Lovric S; Metzler C; Rubberth-Roth A; Schwarting A; Specker C; Tony HP; Unger L; Wassenberg S; Dörner T; Schulze-Koops H;
Lupus; 2013 Oct; 22(11):1142-9. PubMed ID: 24057058
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of low-dose rituximab on hematological abnormalities in patients with connective tissue disease
.
Wang CY; Guo SH; Wang LP; Wang XY; Shen HL
Int J Clin Pharmacol Ther; 2019 Oct; 57(10):500-505. PubMed ID: 31426902
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment in lupus nephritis--where do we stand?
Gunnarsson I; Jonsdottir T
Lupus; 2013 Apr; 22(4):381-9. PubMed ID: 23553781
[TBL] [Abstract][Full Text] [Related]
12. Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review.
Sans-Pola C; Danés I; Bosch JÀ; Marrero-Álvarez P; Cortés J; Agustí A
Front Med (Lausanne); 2023; 10():1159794. PubMed ID: 37305139
[TBL] [Abstract][Full Text] [Related]
13. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of rituximab in a tertiary Queensland hospital.
Butterly SJ; Pillans P; Horn B; Miles R; Sturtevant J
Intern Med J; 2010 Jun; 40(6):443-52. PubMed ID: 19460062
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
16. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
Dale RC; Brilot F; Duffy LV; Twilt M; Waldman AT; Narula S; Muscal E; Deiva K; Andersen E; Eyre MR; Eleftheriou D; Brogan PA; Kneen R; Alper G; Anlar B; Wassmer E; Heineman K; Hemingway C; Riney CJ; Kornberg A; Tardieu M; Stocco A; Banwell B; Gorman MP; Benseler SM; Lim M
Neurology; 2014 Jul; 83(2):142-50. PubMed ID: 24920861
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
[TBL] [Abstract][Full Text] [Related]
18. Off-label use of rituximab in systemic lupus erythematosus: a systematic review.
Murray E; Perry M
Clin Rheumatol; 2010 Jul; 29(7):707-16. PubMed ID: 20155295
[TBL] [Abstract][Full Text] [Related]
19. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
20. Off-label use of rituximab in systemic rheumatic diseases: case series and review.
Araújo F; Silva I; Sepriano A; Nero P; Branco JC
Acta Reumatol Port; 2013; 38(4):290-4. PubMed ID: 24435034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
